| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Protein C and Protein S, Functional : 39457
MessagePlease submit a separate, frozen vial for each special coagulation assay ordered.
Test Code
PRCSAC or 39457
Alias/See Also
PC Activity; PC; PS; Protein S; PS Activity; Protein C
CPT Codes
85303, 85306
Includes
Protein C Activity and Protein S Activity
Instructions
Draw blood in light blue-top tube containing 3.2% sodium citrate, mix gently by inverting 3-4 times. Tube must be filled to within +/-10% of fill line.
Platelet-poor plasma: Centrifuge 15 minutes at 1500 g within 1 hour of collection. Using a plastic pipette, remove plasma, taking care to avoid the WBC/platelet buffy layer and place into a plastic vial. Centrifuge a second time and transfer platelet-poor plasma into a new plastic vial. Freeze immediately and ship on dry ice.
Platelet-poor plasma: Centrifuge 15 minutes at 1500 g within 1 hour of collection. Using a plastic pipette, remove plasma, taking care to avoid the WBC/platelet buffy layer and place into a plastic vial. Centrifuge a second time and transfer platelet-poor plasma into a new plastic vial. Freeze immediately and ship on dry ice.
Transport Container
Preferred Specimen
1 mL frozen platelet-poor plasma collected in 3.2% sodium citrate (light blue-top) tube
Minimum Volume
0.5 mL
1 mL frozen platelet-poor plasma collected in 3.2% sodium citrate (light blue-top) tube
Minimum Volume
0.5 mL
Transport Temperature
Frozen.
Specimen Stability
Room temperature: Unacceptable; Refrigerated: Unacceptable; Frozen: 14 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Hemolysis
Methodology
Clotting
Setup Schedule
Tuesday & Thursday
Report Available
1-6 days
Reference Range
Protein C Activity 70-180 % normal
Protein S Activity
Males 70-150 % normal
Females 60-140 % normal
Clinical Significance
Protein C (PC) and Protein S (PS) deficiency may be congenital or acquired and is associated with venous thrombosis. Acquired PC or PS deficiency may occur with vitamin K antagonists/deficiency, liver disease, malignancy, consumptive DIC, surgery, trauma, and hepatic immaturity of the newborn. In addition, PS deficiency is physiologic in pregnancy.
Expected impact by therapeutic levels (potential interference depends upon drug concentration):
1) Vitamin K antagonists (e.g., warfarin): decrease
2) Heparin (UFH or LMWH): no effect to falsely increased activity levels at higher concentrations
3) Dabigatran or Argatroban (thrombin inhibitors): may falsely increase activity
4) Rivaroxaban, Apixaban, Edoxaban (Factor Xa inhibitors): may falsely increase activity
Expected impact by therapeutic levels (potential interference depends upon drug concentration):
1) Vitamin K antagonists (e.g., warfarin): decrease
2) Heparin (UFH or LMWH): no effect to falsely increased activity levels at higher concentrations
3) Dabigatran or Argatroban (thrombin inhibitors): may falsely increase activity
4) Rivaroxaban, Apixaban, Edoxaban (Factor Xa inhibitors): may falsely increase activity
Performing Laboratory
med fusion
